Introducing the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses how genomic information from tests, such the Oncotype DX® Breast Cancer Assay, can be integrated with traditional clinicopathological information to support adjuvant clinical decision-making in breast cancer patients.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:


Comments are closed.